Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology

Martina Sattlecker, Steven J Kiddle, Stephen Newhouse, Petroula Proitsi, Sally Nelson, Stephen Williams, Caroline Johnston, Richard Killick, Andrew Simmons, Eric Westman, Angela Hodges, Hilkka Soininen, Iwona Kłoszewska, Patrizia Mecocci, Magda Tsolaki, Bruno Vellas, Simon Lovestone, the AddNeuroMed Consortium, Richard J B Dobson

Research output: Contribution to journalArticlepeer-review

154 Citations (Scopus)
122 Downloads (Pure)


Blood proteins and their complexes have become the focus of a great deal of interest in the context of their potential as biomarkers of Alzheimer's disease (AD). We used a SOMAscan assay for quantifying 1001 proteins in blood samples from 331 AD, 211 controls, and 149 mild cognitive impaired (MCI) subjects. The strongest associations of protein levels with AD outcomes were prostate-specific antigen complexed to α1-antichymotrypsin (AD diagnosis), pancreatic prohormone (AD diagnosis, left entorhinal cortex atrophy, and left hippocampus atrophy), clusterin (rate of cognitive decline), and fetuin B (left entorhinal atrophy). Multivariate analysis found that a subset of 13 proteins predicted AD with an accuracy of area under the curve of 0.70. Our replication of previous findings provides further evidence that levels of these proteins in plasma are truly associated with AD. The newly identified proteins could be potential biomarkers and are worthy of further investigation.
Original languageEnglish
Pages (from-to)724-734
Number of pages11
JournalAlzheimer's & Dementia
Issue number6
Early online date28 Apr 2014
Publication statusPublished - 28 Apr 2014


Dive into the research topics of 'Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology'. Together they form a unique fingerprint.

Cite this